Balancing between bleeding and thromboembolism after percutaneous coronary intervention in patients with atrial fibrillation. Could triple anticoagulant therapy be a solution?

Postepy w Kardiologii Interwencyjnej

Volumn 9, Issue 3, 2013, Pages 234-240

  Da̧browska, Magdalena ^a   Ochała, Andrzej ^b   Cybulski, Wiesław ^b   Tendera, Michał ^b  

^a Cardiology Research Group   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Anticoagulants; Atrial fibrillation; Percutaneous coronary intervention; Triple therapy

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN;

AGED; ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; STENT; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84884924223     PISSN: 17349338     EISSN: 18974295     Source Type: Journal    
DOI: 10.5114/pwki.2013.37501     Document Type: Article

References (30)

1. Mehta SR, Yusuf S, Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
2. Mishkel GJ, Aguirre FV, Ligon R.W., et al. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol 1999; 34: 1884-1890.
3. van Walraven C., Hart RG, Singer D.E., et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient metaanalysis. JAMA 2002; 288: 2441-2448.
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
5. Butchart EG, Gohlke-Bärwolf C, Antunes MJ, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005; 26: 2463-2471.
6. Hirsh J, Lee AY. How we diagnose and treat deep vein thrombosis. Blood 2002; 99: 3102-3110.
7. ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555.
8. Moscucci M, Fox KA, Cannon C.P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815-1823.
9. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
10. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
11. Lip G.Y., Nieuwlaat R, Pisters R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
12. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
13. Leon MB, Baim DS, Popma JJ. A clinical trial comparing three anti thrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-1671.
14. Iijima R, Ndrepepa G, Mehilli J. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. Eur Heart J 2009; 30: 290-296.
15. Schömig A., Sarafoff N, Seyfarth M. Triple antithrombotic management after stent implantation: when and how? Heart 2009; 95: 1280-1285.
16. Dewilde WJ, Oirbans T, Verheugt F.W., et al. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115.
17. Khurram Z, Chou E, Minutello R., et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006; 18: 162-164.
18. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-1441.
19. Valencia J, Mainar V, Bordes P., et al. Observance of antiplatelet therapy after stent implantation in patients under chronic oral anticoagulant treatment. J IntervCardiol 2008; 21: 218-224.
20. Orford JL, Fasseas P, Melby S., et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004; 147: 463-467.
21. Rogacka R, Chieffo A, Michev I., et al. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. JACC Cardiovasc Interv 2008; 1: 56-61.
22. Manzano-Fernández S, Pastor FJ, Marín F, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008; 134: 559-567.
23. Connolly SJ, Eikelboom J, Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
24. Granger CB, Alexander JH, McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
25. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
26. Alexander JH, Becker RC, Bhatt D.L., et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 2877-2885.
27. Mega JL, Braunwald E, Mohanavelu S., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38.
28. Oldgren J, Budaj A, Granger C.B., et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781-2789.
29. Gilard M, Blanchard D, Helft G., et al. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol 2009; 104: 338-342.
30. Wiviott SD, Braunwald E, McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.